비호지킨 림프종에 대한 COP-BLAM N(Cyolophosphamide/Vincristine/Prednisone/Bleomycin/Adriamycin/Procarbazine) 복합화학요법의 치료효과
COP-BLAM V(Cyclophosphamide/Vincristine/Prednisone/Bleomycin/Adriamycin/Procarbazine) Combination Chemotherapy for the Treatment of Intermediate and High Grade Non-Hodgkin's Lymphoma
대한암학회지 1992년 24권 2호 p.268 ~ 276
소속 상세정보
박영이
이기형/정경해/윤성수/임영혁/장정순/이재용/허대석/박영주
KMID : 0360319920240020268
Abstract
Between Ap. 1989 and Jul. 1991, 42 patients with the intermediate and high grade Non-Hodgkin' s lymphoma were treated with COP-BLAM V(cyclophosphamide, bleomycin, prednisone, vincristine, adriamycin, procarbazine) infusional chemotherapy.
The median age was 53yrs(range 19~77) and male to female ratio was 30:11. No patients received any previous cytotoxic chemotherapy, and the common histologic typeswere diffuse histiocytic type(74%) and immunoblastic type(14%). The proportion of
patients
with 'B' symptoms, or bulky mass, or LDH>400 at diagnosis was 31%, 17%, 19%, respectively.
The rate of complete remission was 74%(31/42) and overal response rate was 95%(40/42). The median-disease free interval was 14 months(1.5~23). The rage of survival time was from 2+ to 24+ months. 2year survival rate was 78.5% but the median
survival
time was not reached right now(the median follow up time: 12.5months)
The leukopenia(26%) and anemia(14%) were the hematologic toxicities. Non-hematologic side effects were moderate and severe G-I symptoms-nausea, vomiting(31%), alopecia(69%), stomatitis(12%) and pulmonary toxity(14%), two treatment related deaths
were
associated with sepsis and acute respiratory distress syndrome(ARDS)
Based on high complete response rate and tolerable toxicitiy, COP-BLAM V seems to be an effective treatment regimen for the intermediate and high grade Non-Hodgkin's lymphoma. To confirm the efficacy further, long-term follow up and the phase III
randomised comparision with other regimens with be needed.
키워드
원문 및 링크아웃 정보
등재저널 정보